Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Endra Life Sciences Inc (NQ: NDRA )

1.380 -0.010 (-0.72%)
Streaming Delayed Price Updated: 3:58 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Endra Life Sciences Inc

< Previous 1 2 3 Next >
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Participate in The Benchmark Company’s 12th Annual Discovery One-on-One Investor Conference
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA to Host Multidisciplinary Clinical Discussion on Managing Liver Disease During AASLD’s The Liver Meeting® 2023
From ENDRA Life Sciences Inc.
Via Business Wire
Abstract for ENDRA Life Sciences' TAEUS System Accepted for Presentation at EASL Steatotic Liver Disease Summit 2023
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023
From ENDRA Life Sciences Inc.
Via Business Wire
Study Highlighting ENDRA Life Sciences’ TAEUS Technology to be Presented at EASL International Liver Congress 2023
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Report First Quarter 2023 Financial Results on May 15, 2023
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Announces Closing of Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Securities
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Announces Pricing of Upsized $4.5 Million Public Offering
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Announces 1-for-20 Reverse Stock Split
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Report Third Quarter 2022 Financial Results on November 14, 2022
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Plans to Submit De Novo Request to U.S. FDA for its TAEUS® System in Coming Weeks
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Participate in Upcoming Investor and Industry Conferences
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From ENDRA Life Sciences Inc.
Via Business Wire
ENDRA Life Sciences to Report Second Quarter 2022 Financial Results on August 15, 2022
From ENDRA Life Sciences Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.